Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Does Psilocybin Change Synaptic Vesicular Density in the Brains of Patients With Mild Cognitive Impairment?

FY 2022-23

Summary
Amnestic mild cognitive impairment (aMCI) is characterized by memory impairment that does not interfere with daily living and is viewed as a precursor to Alzheimer's Dementia (AD), for which there are no known treatments. There is renewed interest in using psychedelics, including psilocybin, to treat mental illness. Evidence suggests that psilocybin exerts its psychedelic, and possibly its clinical effects, through interactions with a serotonin receptor in the brain called 5HT2A-R. Intriguingly, reduced 5-HT2A-R density in the brain is associated with cognitive impairments (e.g., decreased memory). Promisingly, the results of preclinical animal studies suggests psilocybin may promote the formation of cellular connections in brain regions responsible for learning and memory, possibly through 5-HT2A agonism. As such, psilocybin is worth exploring as a novel therapeutic for aMCI to counter neurodegenerative disease progression. This study will use a double-blind-placebo controlled design to determine whether psilocybin increases the density of cellular connections in the brain, referred to as synaptic vesicular density (SVD), in individuals with aMCI. This will be measured in the brain using a type of medical imaging called positron emission tomography (PET). We also aim to examine if changes in SVD are associated with improvements in cognition. We hypothesize that administration of psilocybin will increase SVD in the brain, and that it will result in improved cognition. This novel PET study of the effects of psilocybin on SVD may advance the understanding of neurodegenerative disorders, with the ultimate aim of improving the health and well-being of individuals and families affected by neurodegenerative disorders, such as aMCI and AD.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486571
Name
Amaev Aron
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Does Psilocybin Change Synaptic Vesicular Density in the Brains of Patients With Mild Cognitive Impairment?
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
5ht2a-R Agonism; Alzheimer'S Dementia; Amnestic Mild Cognitive Impairment; Positron Emission Tomography; Psilocybin; Randomized Control Trial; Synaptic Plasticity; Synaptic Vesicle Glycoprotein 2a; Synaptic Vesicular Density; [18f]Synvest-1
Abstract
Amnestic mild cognitive impairment (aMCI) is characterized by memory impairment that does not interfere with daily living and is viewed as a precursor to Alzheimer's Dementia (AD), for which there are no known treatments. There is renewed interest in using psychedelics, including psilocybin, to treat mental illness. Evidence suggests that psilocybin exerts its psychedelic, and possibly its clinical effects, through interactions with a serotonin receptor in the brain called 5HT2A-R. Intriguingly, reduced 5-HT2A-R density in the brain is associated with cognitive impairments (e.g., decreased memory). Promisingly, the results of preclinical animal studies suggests psilocybin may promote the formation of cellular connections in brain regions responsible for learning and memory, possibly through 5-HT2A agonism. As such, psilocybin is worth exploring as a novel therapeutic for aMCI to counter neurodegenerative disease progression. This study will use a double-blind-placebo controlled design to determine whether psilocybin increases the density of cellular connections in the brain, referred to as synaptic vesicular density (SVD), in individuals with aMCI. This will be measured in the brain using a type of medical imaging called positron emission tomography (PET). We also aim to examine if changes in SVD are associated with improvements in cognition. We hypothesize that administration of psilocybin will increase SVD in the brain, and that it will result in improved cognition. This novel PET study of the effects of psilocybin on SVD may advance the understanding of neurodegenerative disorders, with the ultimate aim of improving the health and well-being of individuals and families affected by neurodegenerative disorders, such as aMCI and AD.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Amaev, Aron
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~